|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cancer | |||||
| 2 | Interventions listed in this trial | ||||
| capecitabine | |||||
| irinotecan hydrochloride | |||||
| 3 | Additional drug interventions recognized in this trial | ||||
| Camptothecin | |||||
| Irinotecan | |||||
| 4 | More general drug interventions related to this trial | ||||
| Antimetabolites | |||||
| Antimetabolites, Antineoplastic | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Phytogenic | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| Albert Einstein College of Medicine of Yeshiva University | |||||